The Pharma company has reportedly asked permission from the Drugs Controller General of India.
One of the leading Pharma companies in India, Dr Reddy’s has asked DCGI to conduct phase-3 human clinical trials of Sputnik V in India on Friday.
According to the officials, the Russian Direct Investment Fund (RDIF) will supply 100 M doses of Sputnik to Dr Reddy’s upon the approval.
According to the source, Drugs Controller General of India is currently evaluating the technical aspects of the application, and soon a decision comes on the approval.
It is known news that the Hyderabad-based pharma company has associated with RDIF to conduct clinical trials of Sputnik V and also for its distribution.
The Sputnik V vaccine has combinedly developed by Gamaleya National Research Centre of Epidemiology and Microbiology and RDIF in Russia.
Reportedly, the officials are conducting the phase-3 trials of the vaccine in Russia since September 1.Coming to Indian vaccines, Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have been conducting their phase 2 of human clinical trials.
Of all the three, sources say, Sputnik V is said to be more effective as the clinical trials demonstrated that 100% of volunteers developed immunity in just 21 days.